drugset / Trial / NCT03348163
(mo)BETTA Trial in Transwomen for Optimization of ART
Phase 4
Terminated
26 enrolled
The University of Texas Health Science Center, Houston
Gilead Sciences · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected transgender women (TW).
Timeline
- Start
- 2018-06-06
- Primary completion
- 2020-12-15
- Completion
- 2020-12-15
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of ability to recruit due to COVID-19 pandemic”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bictegravir | Small molecule | — | — |
| Comparator | Tenofovir disoproxil fumarate | Small molecule | — | — |
| Subject | emtricitabine | Other / unclassified | — | — |
| Subject | tenofovir alafenamide | Small molecule | — | — |